Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 June 2022, including: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?" - Scrip, 13 Jun, 2022.)
(Also see "BIO 2022 Notebook: Staying Afloat In Rough Waters" - Scrip, 14 Jun, 2022.)
(Also see "Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata" - Scrip, 13 Jun, 2022.)
(Also see "Argenx Enters Japan With Smooth Approval – How Was It Possible?" - Scrip, 10 Jun, 2022.)
(Also see "BTK Inhibitors Are The Next Big Race In MS" - Scrip, 9 Jun, 2022.)